glp-1 moa receptor agonists for individualized treatment of type 2 diabetes mellitus Trends in the Development of

Given the potential cost implications, GLP-1 RAs and SGLT2is could be considered as second-line options in case of failure of first-line drugs (metformin, pioglitazone, and clomifene citrate), as the latter are likely to be much cheaper

A robust pipeline of oral GLP-1 agents and next-generation therapies with complementary mechanisms is advancing swiftly, intensifying competition and expanding future treatment possibilities

Transcellular passage is also minimal, as peptides exceed Lipinskis Rule of Five (Ro5) limits and carry many hydrogen-bond donors/acceptors, both of which further contribute to extremely low oral bioavailability

13,14 This reduction in MACE, which is not explained by improvements in glycaemia and nonglycaemic cardiovascular risk factors, remains to be fully elucidated but may reflect other effects of GLP-1 analogues such as their antioxidative and anti-inflammatory properties

Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism

Most advanced is tirzepatide, a GIP-GLP-1 co-agonist, which was recently approved for diabetes therapy in the US